A stronger beat and a lower pressure from the same short peptide — and a receptor that waited five years to learn the name of its ligand.
Identity
- Class
- Preproapelin-derived peptide; circulating form is [Pyr1]apelin-13
- Source
- Endothelium, heart, fat, and hypothalamic neurons
- Receptor
- Apelin receptor (APLNR, also called APJ), a class A GPCR
Key properties
Evidence floorClinicalREF1CLIN1Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.
Mechanism
Apelin is cut from a 77-amino-acid precursor into several active lengths. The dominant circulating form, [Pyr1]apelin-13, binds the apelin receptor and, through Gi, strengthens cardiac contraction while dilating vessels, so output rises as pressure falls. Longer forms such as apelin-36 lean more on β-arrestin and pull the receptor inside the cell. A second endogenous ligand, elabela, uses the same receptor.
Reference notes
- The receptor was cloned in 1993 as an angiotensin-receptor lookalike that does not bind angiotensin; apelin was isolated in 1998.
- [Pyr1]apelin-13 is the main form in human plasma and heart. Apelin-36 is a weaker immediate agonist and a stronger driver of receptor internalization.
- ACE2 clips the C-terminal phenylalanine of apelin-13 with catalytic efficiency comparable to angiotensin II, which is why the native peptide lasts only minutes.
- In people, intravenous [Pyr1]apelin-13 raises cardiac output and lowers peripheral resistance, including in heart failure and, acutely, in pulmonary arterial hypertension. No APJ agonist is an approved drug.
Regulatory status
United States · verified September 2026- Basis
- No approved apelin product. Human evidence is from short intravenous infusions; the small-molecule agonist AMG 986 reached phase 1 without a clinically meaningful cardiac effect.
Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the date above is the last time this row was checked. Other jurisdictions are noted only where they differ materially.
Common questions
- What is Apelin?
- The APJ peptide that strengthens the heartbeat while lowering pressure. Structurally it is Preproapelin-derived peptide; circulating form is [Pyr1]apelin-13.
- How does Apelin work?
- Apelin is cut from a 77-amino-acid precursor into several active lengths. The dominant circulating form, [Pyr1]apelin-13, binds the apelin receptor and, through Gi, strengthens cardiac contraction while dilating vessels, so output rises as pressure falls. Longer forms such as apelin-36 lean more on β-arrestin and pull the receptor inside the cell. A second endogenous ligand, elabela, uses the same receptor.
- How strong is the evidence for Apelin?
- PeptideHormone grades Apelin at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an endogenous signal the body produces itself, and the tier is an editorial judgment about the public literature that can change as the science does.
- What is the half-life of Apelin?
- The reported circulating half-life of Apelin is Minutes (ACE2 and other peptidases).
- Is Apelin FDA-approved?
- No — as of September 2026, Apelin is a native hormone with no drug product of its own, though engineered analogs may be approved. No approved apelin product. Human evidence is from short intravenous infusions; the small-molecule agonist AMG 986 reached phase 1 without a clinically meaningful cardiac effect. Status is US-centric and can change; check the FDA record for the current position.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor · Biochemical and biophysical research communications, 1998 · PMID 9792798
- 2.Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure · Circulation, 2010 · PMID 20385929
- 3.Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension · JACC. Basic to translational science, 2018 · PMID 29876530